CSIMarket
 


Immunic Inc   (IMUX)
Other Ticker:  
 

Immunic Inc 's Tangible Leverage Ratio

IMUX's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


In Spite of the repayements of liabilities of -2.52%, in III Quarter 2023 ,Tangible Leverage Ratio deteriorated to 0.37 is above the company's typical Tangible Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the third quarter 2023, 198 other companies have achieved lower Tangible Leverage Ratio than Immunic Inc in the III Quarter 2023. While Tangible Leverage Ratio total ranking has deteriorated compared to the second quarter 2023 from 551 to 691 .

Explain Tangible Leverage Ratio?
What is IMUX Market Share?
What are IMUX´s Total Liabilities?


IMUX Tangible Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity Change -36.17 % -26.98 % -13.12 % 20.75 % -32.58 %
Y / Y Total Liabilities Change 54.43 % 75.36 % 42.29 % 14.7 % 8.71 %
Tangible Leverage Ratio MRQ 0.37 0.26 0.18 0.12 0.15
IMUX's Total Ranking # 691 # 551 # 418 # 87 # 267
Seq. Tangible Equity Change -30.13 % -24.05 % -19.76 % 49.9 % -20.07 %
Seq. Total Liabilities Change -2.52 % 11.89 % 24.66 % 13.57 % 10.69 %



Tangible Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 199
Healthcare Sector # 345
Overall Market # 691


Tangible Leverage Ratio Statistics
High Average Low
0.4 0.14 0.05
(Sep 30 2018)   (Jun 30 2019)




Financial Statements
Immunic Inc 's Tangible Equity $ 48 Millions Visit IMUX's Balance sheet
Immunic Inc 's Total Liabilities $ 18 Millions Visit IMUX's Balance sheet
Source of IMUX's Sales Visit IMUX's Sales by Geography


Cumulative Immunic Inc 's Tangible Leverage Ratio

IMUX's Tangible Leverage Ratio for the trailling 12 Months

IMUX Tangible Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity TTM Growth -36.17 % -26.98 % -13.12 % 20.75 % -32.58 %
Y / Y Total Liabilities TTM Growth 54.43 % 75.36 % 42.29 % 14.7 % 8.71 %
Tangible Leverage Ratio TTM 0.2 0.17 0.14 0.12 0.12
Total Ranking TTM # 740 # 550 # 2 # 59 # 210
Seq. Tangible Equity TTM Growth -30.13 % -24.05 % -19.76 % 49.9 % -20.07 %
Seq. Total Liabilities TTM Growth -2.52 % 11.89 % 24.66 % 13.57 % 10.69 %


On the trailing twelve months basis Despite of the repayements of liabilities of -2.52% in the trailing twelve months ending in III Quarter 2023, Tangible Leverage Ratio improved to 0.2, above Immunic Inc 's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 198, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than Immunic Inc . While Tangible Leverage Ratio total ranking has deteriorated during the twelve months ending in the III Quarter 2023, compared to the prior period, from 550 to 740.

Explain Tangible Leverage Ratio?
What is IMUX Market Share?
What are IMUX´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 199
Healthcare Sector # 345
Within the Market # 740


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
0.4 0.14 0.05
(Sep 30 2018)   (Jun 30 2019)




Companies with similar Tangible Leverage Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Tangible Equity
Nighthawk Biosciences inc   1.01 $ 33.623  Millions$ 33.447  Millions
Virpax Pharmaceuticals Inc   1.00 $ 6.533  Millions$ 6.506  Millions
Royalty Pharma Plc  1.00 $ 9,614.891  Millions$ 9,585.097  Millions
Bio path Holdings inc   0.99 $ 2.496  Millions$ 2.525  Millions
Avadel Pharmaceuticals Plc  0.99 $ 92.035  Millions$ 93.313  Millions
Gri Bio Inc   0.98 $ 2.177  Millions$ 2.227  Millions
Entrada Therapeutics Inc   0.97 $ 238.370  Millions$ 246.663  Millions
Tg Therapeutics Inc   0.96 $ 156.776  Millions$ 163.970  Millions
Pieris Pharmaceuticals Inc   0.95 $ 28.866  Millions$ 30.510  Millions
Roivant Sciences Ltd   0.94 $ 1,117.009  Millions$ 1,185.012  Millions
Prophase Labs Inc   0.92 $ 35.282  Millions$ 38.182  Millions
Spero Therapeutics Inc   0.92 $ 49.276  Millions$ 53.705  Millions
Acadia Pharmaceuticals Inc   0.92 $ 270.366  Millions$ 295.319  Millions
Unity Biotechnology Inc   0.91 $ 33.064  Millions$ 36.206  Millions
Harmony Biosciences Holdings inc   0.88 $ 296.434  Millions$ 338.263  Millions
Igm Biosciences Inc   0.87 $ 220.488  Millions$ 253.862  Millions
Verastem inc   0.86 $ 71.814  Millions$ 83.180  Millions
Onconova Therapeutics inc   0.86 $ 12.521  Millions$ 14.517  Millions
Pulmatrix Inc   0.85 $ 16.889  Millions$ 19.881  Millions
Aptevo Therapeutics Inc   0.84 $ 12.411  Millions$ 14.718  Millions
Longeveron Inc   0.83 $ 3.394  Millions$ 4.093  Millions
Rhythm Pharmaceuticals inc   0.82 $ 156.725  Millions$ 190.232  Millions
Acurx Pharmaceuticals inc   0.82 $ 3.223  Millions$ 3.935  Millions
Organogenesis Holdings Inc   0.80 $ 185.782  Millions$ 230.992  Millions
Geovax Labs Inc   0.78 $ 7.082  Millions$ 9.119  Millions
Abvc Biopharma Inc   0.77 $ 6.985  Millions$ 9.062  Millions
Neximmune Inc   0.76 $ 6.308  Millions$ 8.254  Millions
Cartesian Therapeutics Inc   0.76 $ 45.705  Millions$ 60.329  Millions
Macrogenics Inc   0.75 $ 145.992  Millions$ 193.980  Millions
23andme Holding Co  0.75 $ 175.979  Millions$ 235.672  Millions

Date modified: 2023-11-16T14:39:04+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com